RESEARCH TRIANGLE PARK, N.C. , Nov. 13, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in the 15th Annual Craig-Hallum Alpha Select Conference .

~ Achieved Third Quarter 2024 Net Product Sales of $7.0 Million ~ ~ Increasing Momentum and Successful Reimbursement in the Adolescent and Young Adult (AYA) Segment Following Strategic Investments to Drive Awareness of Ototoxicity & Adoption of PEDMARK ~ ~ Strengthened Executive Leadership Team

~ Pierre S. Sayad , PhD, M.S., Appointed Chief Medical Officer ~ ~ Terry Evans Appointed Chief Commercial Officer ~ ~ Christiana Cioffi , MBA, Appointed Chief Strategy Officer ~ RESEARCH TRIANGLE PARK, N.C. , Oct. 28, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc.

RESEARCH TRIANGLE PARK, N.C. , Sept. 05, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in upcoming investor conferences.

~ Achieved Second Quarter 2024 Total Net Revenues of $7.3 Million ~ ~ Appointed Jeffrey S. Hackman as Chief Executive Officer (CEO) and Member of the Board of Directors ~ ~ Company Has Approximately $43 Million in Cash, Cash Equivalents, and Investment Securities ~ ~ Management to Host Conference

Company to Also Participate in 2024 Wedbush PacGrow Healthcare Conference RESEARCH TRIANGLE PARK, N.C. , Aug. 06, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its

~ Accomplished Industry Leader Brings Extensive Commercialization and Oncology Expertise ~ ~ Assumes Leadership Role at Critical Time to Expand Use of PEDMARK ® , the First and Only Approved Treatment to Reduce the Risk of Cisplatin-Induced Ototoxicity ~ RESEARCH TRIANGLE PARK, N.C. , Aug.

RESEARCH TRIANGLE PARK, N.C. , July 01, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that Adrian Haigh has departed from his position as Fennec’s Chief Operating Officer as of June 30, 2024 .

RESEARCH TRIANGLE PARK, N.C. , June 25, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 29, 2024 (the “Circular”) for the Annual General Meeting of Shareholders were